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ical diseases by using TEE and to assess if the D-dimer test can
predict the presence of a central venous catheter-related throm-
bus. We assessed 37 patients with various hematological diseases
(18 AML, 8 NHL, 6 ALL, 2 MM, 1 HL, 1 primary amiloidosis,
and 1 MDS). Mean age was 37 years. Mean time with catheter
was 2.66 months. Fourteen of thirty-seven patients were trans-
planted. Thrombus was found in 8 of 37 patients (21.6%).
Thrombus incidence in transplanted group was 28.57% (4/14).
Thirty-four of the patients (91.9) were asymptomatic. No rela-
tion was found between thrombus and D-dimer levels (P 
.071). The time with catheter was not related with the presence
of thrombus also (P  .328). Our ﬁndings showed that TEE is
a useful method in evaluating the presence of thrombus at the
tip of central venous catheters, so it can be useful for the
prediction of complications due to thrombus before catheter
removal. D-dimer shows tendency to be useful in predicting the
presence of a thrombus.
411
ATYPICAL MYCOBACTERIUM INFECTIONS IN PEDIATRIC PATIENTS UN-
DERGOING RELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT)
Dalal, J.D.1, Jackson, M.A.1, Gilman, A.2, Swanson, D.1,
Gonzalez, C.1, Jones, R.1, Shenoy, S.3, Woolfrey, A.4, Gamis, A.S.1,
Peters, C.1 1. Children’s Mercy Hospital, Kansas City, MO; 2. 2UNC
School of Medicine, Chapel Hill, NC; 3. Washington University Medical
Center, St. Louis, MO; 4. Fred Hutchinson Cancer Research Center,
Seattle, WA.
Atypical mycobacterium infections are uncommon in children
undergoing HSCT compared to solid organ transplant recipi-
ents or HIV patients, though more prevalent than in the general
population. Improvements in laboratory diagnostic methods
have led to more accurate and timely identiﬁcation of mycobac-
terium isolates. Diagnosis of non-tuberculus mycobacterium
(NTM) infection in immunocompromised children is difﬁcult
due to non-speciﬁc, diverse clinical manifestations. We report 3
pediatric patients who underwent related donor HSCT from
2002 to 2005 and developed deﬁnite NTM infections in the
setting of fever of unknown origin. Patient 3 was transplanted at
Fred Hutchinson Cancer Research Center, received donor lym-
phocyte infusion at CMH and was re-grafted at Washington
University Medical Center. CD4 counts were 	200/l at the
time of diagnosis. Of note, the CD4 count had just recovered in
patient 2 as has been reported in patients with AIDS developing
atypical mycobacterium osteomyelitis. All patients were immu-
nosuppressed at the time of NTM diagnosis. Aggresive local
treatment such as debridement followed by bone grafting and
insertion of appropriately coated antibiotic beads was essential
for treatment of NTM osteomyelitis. Patient 3 underwent a
second transplant and an alemtuzumab-based reduced intensity
conditioning regimen without NTM prophylaxis and did not
reactivate infection. Outcomes of NTM disease were all favor-
able after appropriate antimicrobial therapy. Susceptibility test-
ing of isolates with MIC was very helpful in choosing appropri-
ate outpatient treatment. The combination of newer macrolides,
ethambutol, rifabutin, and ﬂuoroquinolones appears to have
greater in vivo activity and to provide improved eradication of
bacteria compared to single agents. Concomitant surgical de-
bridement and removal of the central venous catheter when
indicated was essential. We conclude: (1) NTM infection can
cause fever of unknown origin in HSCT patients. (2) NTM
infection can be successfully treated in the outpatient clinic with
antimicrobials chosen according to susceptibility testing of pa-
tient isolates. (3) Local treatment such as catheter removal,
excisional biopsy, and surgical debridement are critical and can
be performed without delayed wound healing or the necessity of
skin grafting in the setting of active skin GVHD. (4) Subsequent
second HSCT can be performed without prophylaxis provided
that the prior NTM infection has been adequately treated (Ta-
ble 1).
Table 1. Patient Characteristics and Outcomes
Category Pt. 1 Pt. 2 Pt. 3
Diagnosis SCID AML IPEX
Age at HSCT 6 months 16 years 2 years
Stem Cells and
Match
maternal PBSC, 3
of 6
maternal PBSC, 3
of 6
BM, 6 of 6 sister
Preparation Flu/ATG Flu/TBI/Melphalan/
ATG
1: Flu/TBI; 2:
Campath/Flu/
Melphalan
GVHD prophylaxis/
treatment
TCD TCD 1: Tacrolimus,
MMF; 2:
Tacrolimus,
steroid
Vital Status alive alive alive
Engraftment full donor
chimerism
full donor
chimerism
1: mixed
chimerism; 2:
mixed chimerism
GVHD grade II acute grade II acute none
A. Mycobacterium
site
central line, lung tibia subcutaneous
Species M. chelonae/
abscessus
M. avium complex M.
chelonae/abscessus
Evaluation blood culture, CT
scan, lung biopsy
CT scan, MRI, bone
aspiration
CT scan, MRI,
excisional biopsy
Onset 6 months 39 days 22 months
Treatment &
Outcome
catheter removal,
ciprofloxacin,
azithromycin,
linezolid  6 wks;
resolved
azithromycin,
ethambutol,
linezolid  8
months,
debridement,
bone graft with
antibiotic beads
surgical excision;
cefoxitin,
azithromycin,
linezolid  8
months
Abbreviations: SCID, common gamma chain X-linked severe
combined immunodeﬁciency; AML, acute myelogenous leuke-
mia; IPEX, immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked; PBSC, peripheral blood stem cells; BM, bone
marrow; Flu, ﬂudarabine; ATG, anti-thymocyte globulin; TBI,
total body irradiation; TCD, T-cell depletion; MMF, mycophe-
nolate mofetil
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A PHASE I SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHAR-
MACODYNAMIC ASSESSMENT OF VELAFERMIN IN PATIENTS WITH
ACTIVE ORAL MUCOSITIS
Mehta, J.1, Schuster, M.W.2, Harpel, J.2, Skikne, B.3, Shore, T.2,
Duffey, S.1, Greenberg, J.2, Divine, C.3, Halvorsen, Y.4, Cosentino, C.4,
Hahne, W.4 1. Northwestern U., Chicago, IL; 2. Cornell Med. Center,
New York, NY; 3. U. of Kansas Med. Ctr, Kansas City, KS; 4. CuraGen
Corp., Branford, CT.
Velafermin (CG53135-05) or recombinant human ﬁbroblast
growth factor-20 (rhFGF-20) protein is under investigation for the
treatment of active oral mucositis (OM). OM is a commonly
occurring side effect of high-dose chemotherapy (HDCT) in pa-
tients (pts) undergoing autologous hematopoietic stem cell trans-
plant (AHSCT) and in leukemia pts receiving CT. Pharmacology
studies demonstrated that treatment of velafermin to animals with
active OM for 2, 3, or 4 consecutive days resulted in a signiﬁcant
reduction in duration of clinically relevant OM compared with
animals in the vehicle treated control group. Previous clinical
studies showed that velafermin was generally well tolerated as a
single dose regimen up to 0.2 mg/kg dose level. The objectives of
this Phase I trial are to evaluate the safety, tolerability and phar-
macokinetics (PK) of velafermin when administered as three daily
doses via intravenous (IV) infusion to pts who develop oral mu-
cositis after receiving HDCT. OM and diarrhea status are evalu-
ated using the World Health Organization (WHO) grading sys-
tem. Approximately 9–12 pts receiving AHSCT following myelo-
ablative CT or leukemia pts receiving CT, age 18 years and older,
are to be enrolled when Grades 1 or 2 OM is observed. Velafermin
treatment is initiated within 24 hours after OM is observed. Three
pts will be treated at each dose level based on tolerability and
recruitment parameters. Pts will receive velafermin at 0.03, 0.1, or
0.2 mg/kg/day for 3 consecutive days. Pt follow-up will be contin-
ued for approximately 60 days following infusion of velafermin.
The 3 pts in the ﬁrst cohort receiving 0.03 mg/kg tolerated mul-
tiple doses of velafermin well with no complaints or adverse events
(AE) during or immediately after infusion. Dose escalation deci-
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sion was made at 14 days after pts completed velafermin adminis-
tration with no dose limiting toxicity reported. All abnormal he-
matology or chemistry laboratory reports were expected and con-
sistent with pt disease conditions. The second cohort of 0.1 mg/kg
dose is ongoing with 2 pts completed study drug infusion. The
safety proﬁle and clinical data of all pts will be reported.
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CAREGIVER SUPPORT GROUP ON PEDIATRIC BONE MARROW TRANS-
PLANT UNIT: WHAT FAMILIES ARE TALKING ABOUT AND WHY THE
MEDICAL TEAM SHOULD LISTEN
Schmid, C.L.1, Calderon, K.S.1, Partin-Welch, P.H.1, Huber, H.1,
Robinson, N.S.1, Van Loon, R.A.2 1. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH; 2. University of Cincinnati, Cincin-
nati, OH.
Prompted by families’ unrest in the Pediatric Blood and Marrow
Transplant Unit at Cincinnati Children’s Hospital Medical Cen-
ter, in the Spring of 2005, social workers began an hour-long,
weekly support group for caregivers of inpatients. Group atten-
dance has depended upon unit census and other factors such as
caregivers’ ability to leave the child in the room with an attendant.
Notable discussion points have emerged and the group has become
not only a support for caregivers but a guide for the medical team
on how to best assist families and patients through treatment and
recovery. The team’s understanding of the main, or previously
unrecognized, family issues is resulting in a better outcome for the
patients and caregivers. Overt and covert topics have emerged from
the group. Overt topics, or those “on the surface” or “expected” to
appear, remain consistent within almost each discussion. These
explicit topics include difﬁculty with distance from primary resi-
dence and managing the household, beneﬁt in connecting with
other caregivers on the unit, balancing siblings’ needs while caring
for sick child, and ﬁnancial strain. While it is necessary for the
medical team to be mindful of those struggles, it is potentially even
more important to consider covert issues that also make a powerful
impact and often go unnoticed. Covert topics, or those not as
readily voiced but shared among caregivers, may include self-care
and the need to be away from the child to express emotions,
responding to emotionally “needy” families on the unit, physical
impact of illness on the patient, fear of returning to hospital
following discharge, neediness of the ill child, comprehending
medical information and advocating for the child with the medical
team, how to successfully convey concerns to the team, and a
repeated expression in conﬁdence of the medical facility (poten-
tially stated for their own reassurance). In creating a safe environ-
ment for caregivers to share their concerns, struggles, and joys, the
medical team gains a better understanding of how to interpret
caregivers’ behavior and respond within a family-centered care
model. Subsequently, the patient’s treatment and recovery may go
more smoothly with families feeling better supported. Acknowl-
edging the multitude of strains and adjustments that accompany a
prolonged hospitalization will beneﬁt all involved with the pa-
tient’s care and, ultimately, the patient.
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GLUTAMINE SUPPLEMENTATION TO REDUCE ORAL MUCOSITIS IN
MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN
AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A FEASIBILITY
STUDY
Hansen, L.K.1, Smythe, P.A.1, Hansen, K.S.1, Gruenberg, D.R.1,
Callaway, D.1 1Legacy Good Samaritan Hospital, NW Marrow Trans-
plant Program, Portland, OR.
Oral mucositis is a common and distressing toxicity associated
with high dose Melphalan (HDM) and autologous stem cell
transplantation (ASCT). The amino acid, glutamine (GLN), has
been employed in an attempt to ameliorate oral mucositis in
various high dose chemotherapy regimens with mixed results.
This pilot study sought to evaluate the feasibility of adminis-
tering an oral GLN food supplement in patients with multiple
myeloma undergoing HDM and ASCT. Twelve patients (3
females and 9 males), median age 51, consented and enrolled in
the trial. GlutaSolve™ (Novartis) 15 gm bid was administered 4
days before the start of HDM and continued for at least 14 days
or 28 doses. Oral assessment and mucositis ratings were scored
by trained oncology nurses and physicians using the NCI Com-
mon Toxicity Criteria, version 3.0. Compliance with bid dosing,
tolerance of GLN, pain medication usage, total parenteral nu-
trition (TPN), and hospital length of stay (LOS) were measured.
The 12 study patients were compared to case controls matched
by gender, age, and presence or absence of renal dysfunction.
Results: The compliance rate for planned GLN doses was 91.3
%. Toxicities were minimal and were limited to occasional
nausea, vomiting, and mild abdominal pain after taking GLN.
Several patients developed aversion to ingesting GLN toward
the end of the treatment period. There were no cases of clinical
grades 3 or 4 oral mucositis observed in the 12 study subjects.
Median clinical mucositis score was grade 1 (mean  1.2) and
median functional mucositis score was grade 1 (mean  1.1).
Control patients had median clinical and functional mucositis
scores of 2 (mean  1.5) and 1 (mean  1.25), respectively. Only
1 study patient developed functional grade 3 mucositis (unable
to adequately aliment or hydrate orally), whereas 3 control
patients experienced grade 3 mucositis. None of the study pa-
tients received TPN and only 1 patient received parenteral
analgesia for oral discomfort. In comparison, 2 controls received
TPN due to oral mucositis and 4 received parenteral analgesia.
Average LOS was 16.8 days for study patients and 17.4 days for
controls. Conclusions: Oral GlutaSolve™ supplement is safe
and well tolerated in patients receiving HDM and ASCT for
treatment of multiple myeloma. Results of this pilot study sug-
gest this inexpensive form of GLN may reduce the severity of
oral mucositis and further study is warranted in patients receiv-
ing HDM and ASCT.
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ANTIBACTERIAL PROPHYLAXIS DURING NEUTROPENIC PHASE IN AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (APBSCT).
COMPARISON BETWEEN CIPROFLOXACIN  AMOXICILIN VS. LEVO-
FLOXACIN
Karduss, A.J.1, Gomez, L.R.1, Reyes, P.A.1, Jimenez, J.A.1,
Jaimes, F.2, Deossa, H.1 1. Instituto de Cancerologia - Clinica las
Americas, Medellin, Colombia; 2. Departamento de Medicina Interna -
Universidad de Antioquia, Medellin, Colombia.
From November 2002 to May 2004, the patients who received an
APBST had a prophylactic antibacterial regimen with ciproﬂoxacin
500 mg PO BID  amoxicilin 500 mg PO TID (group A). After
June 2004 our protocol changed to levaquin 500 mg PO daily
(group B). We compared the incidence of fever, infections, and
mortality related to the infections in these 2 groups. All the pa-
tients were in an individual room and they received ﬁlgrastin from
day 7 until neutrophils recovery. In case of fever a complete
physical exam, blood and urine cultures, and chest X-Ray were
done, and a Carbapenem was started. There were 20 patients in
group A, 13 men and 7 women, median age 38.90 years (15–67); 6
HD, 7 MM, 7 NHL. The average time with neutrophils 500 was
9.4 days and for engraftment was 11.4 days. Sixteen of twenty had
fever (80%), in 7 (43.7%) the cause was unknown, in 5 (31.2%) a
bacteria was found (E. coli [3], S. epidermidis[2]); 1 patient had
pneumonia caused by A. fumigatus, and 3 had engraftment syn-
drome and there were no deaths. Group B were 19 patients, 12
men and 7 women, median age 50.5 (24–60), 10 MM, 5 NHL, 4
HD. Average time with neutrophils500 was 9.47 days (7–12) and
for engraftment was 11.42 days (11–14). Seventeen patients had
fever (89.4%): 12 (70%) of unknown cause, in 3 (17.6%) a bacteria
was found (Burkhordelia cepacea [1], E. coli [2]), 1 had engraftment
syndrome and 1 pneumonia without germ. We had no deaths due
to infection, and 1 patient died secondary to VOD. For comparing
the groups a Fisher’s test was done, and there were no signiﬁcant
differences in frequency of fever cases (P  .365) nor bacteremia
cases (P  .378). These results remained non signiﬁcant after
adjustment with a logistic model for neutropenia days and the
average of days for engraftment between the groups; Wald test for
fever P .578 and for bacteremia, P .370. The prophylaxis daily
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